

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2017

	Shares	Value
<b>COMMON STOCKS<sup>†</sup> - 99.9%</b>		
<b>Biotechnology - 67.6%</b>		
Amgen, Inc.	98,099	\$ 17,059,416
Gilead Sciences, Inc.	199,565	14,296,837
Celgene Corp.*	130,074	13,574,523
Biogen, Inc.*	38,875	12,384,409
Vertex Pharmaceuticals, Inc.*	65,387	9,798,896
Regeneron Pharmaceuticals, Inc.*	25,812	9,704,280
Illumina, Inc.*	40,197	8,782,643
Alexion Pharmaceuticals, Inc.*	69,462	8,306,961
Incyte Corp.*	71,393	6,761,631
BioMarin Pharmaceutical, Inc.*	66,163	5,899,755
Alnylam Pharmaceuticals, Inc.*	43,222	5,491,355
Exelixis, Inc.*	164,847	5,011,349
Seattle Genetics, Inc.*	81,257	4,347,249
Sage Therapeutics, Inc.*, <sup>1</sup>	24,830	4,089,749
United Therapeutics Corp.*	27,446	4,060,636
Bio-Rad Laboratories, Inc. — Class A* <sup>1</sup>	16,682	3,981,493
Exact Sciences Corp.*	75,084	3,944,913
Bluebird Bio, Inc.*	21,392	3,809,915
Ionis Pharmaceuticals, Inc.*	75,541	3,799,712
Bioverativ, Inc.*	68,607	3,699,289
Juno Therapeutics, Inc.*	79,150	3,617,946
Charles River Laboratories International, Inc.*	32,918	3,602,875
FibroGen, Inc.*	66,600	3,156,840
Avexis, Inc.*	28,040	3,103,187
ACADIA Pharmaceuticals, Inc.*	99,843	3,006,273
Puma Biotechnology, Inc.*	29,610	2,926,948
Immunomedics, Inc.*, <sup>1</sup>	171,200	2,766,592
Spark Therapeutics, Inc.*, <sup>1</sup>	53,120	2,731,430
Halozyme Therapeutics, Inc.*	131,814	2,670,552
Ligand Pharmaceuticals, Inc. — Class B*	19,225	2,632,479
Amicus Therapeutics, Inc.*	173,581	2,497,831
Myriad Genetics, Inc.*	72,386	2,486,097
Insmed, Inc.*	79,200	2,469,456
Prothena Corporation plc* <sup>1</sup>	64,817	2,429,989
Loxo Oncology, Inc.*	28,800	2,424,384
Medicines Co.*	81,708	2,233,897
Spectrum Pharmaceuticals, Inc.*	116,500	2,207,675
Blueprint Medicines Corp.*	29,200	2,201,972
Ultragenyx Pharmaceutical, Inc.*	47,306	2,194,052
Esperion Therapeutics, Inc.*	32,937	2,168,572
Editas Medicine, Inc.*, <sup>1</sup>	68,400	2,101,932
Sangamo Therapeutics, Inc.*	116,000	1,902,400
Radius Health, Inc.*, <sup>1</sup>	58,493	1,858,323
Intercept Pharmaceuticals, Inc.*, <sup>1</sup>	31,160	1,820,367
Dynavax Technologies Corp.*, <sup>1</sup>	87,030	1,627,461
Acorda Therapeutics, Inc.*	74,771	1,603,838
ImmunoGen, Inc.*	225,300	1,444,173
PTC Therapeutics, Inc.*	78,800	1,314,384
Five Prime Therapeutics, Inc.*	52,981	1,161,343
AMAG Pharmaceuticals, Inc.*	76,101	1,008,338
<b>Total Biotechnology</b>		<b>218,176,617</b>
<b>Pharmaceuticals - 25.8%</b>		
AbbVie, Inc.	197,334	19,084,171
Shire plc ADR	69,404	10,765,949
Nektar Therapeutics*	82,307	4,915,374
Neurocrine Biosciences, Inc.*	55,621	4,315,633
PRA Health Sciences, Inc.*	42,328	3,854,811
Alkermes plc*	64,078	3,506,989
Jazz Pharmaceuticals plc*	25,960	3,495,514
TESARO, Inc.*	40,153	3,327,479
Akom, Inc.*	95,453	3,076,450
Sarepta Therapeutics, Inc.*	53,100	2,954,484
Clovis Oncology, Inc.*	42,697	2,903,396
Portola Pharmaceuticals, Inc.*	55,235	2,688,840
Array BioPharma, Inc.*	206,830	2,647,424
Agios Pharmaceuticals, Inc.*	43,114	2,464,827
Horizon Pharma plc*	163,294	2,384,092
Ironwood Pharmaceuticals, Inc. — Class A*	152,941	2,292,586
Pacira Pharmaceuticals, Inc.*	46,810	2,136,877
Global Blood Therapeutics, Inc.*	48,575	1,911,426
Impax Laboratories, Inc.*	101,707	1,693,422
Flexion Therapeutics, Inc.*, <sup>1</sup>	60,400	1,512,416
Eagle Pharmaceuticals, Inc.*, <sup>1</sup>	23,960	1,279,943
<b>Total Pharmaceuticals</b>		<b>83,212,103</b>
<b>Healthcare-Products - 3.4%</b>		
Bio-Techne Corp.	26,432	3,424,266
QIAGEN N.V.*	97,913	3,028,449
OPKO Health, Inc.*, <sup>1</sup>	511,700	2,507,330
MiMedx Group, Inc.*, <sup>1</sup>	150,795	1,901,525
<b>Total Healthcare-Products</b>		<b>10,861,570</b>
<b>Healthcare-Services - 2.1%</b>		
IQVIA Holdings, Inc.*	69,644	6,818,148
<b>Commercial Services - 1.0%</b>		
Incorporated Research Holdings, Inc. — Class A*	77,010	3,357,636
<b>Total Common Stocks</b> (Cost \$189,889,716)		<b>322,426,074</b>
<b>RIGHTS<sup>†††</sup> - 0.0%</b>		
Chelsea Therapeutics International		
Expires 03/01/18* <sup>2</sup>	231,107	—
Dyax Corp.		
Expires 03/06/18* <sup>2</sup>	167,165	—
Clinical Data, Inc.		
Expires 12/31/20* <sup>2</sup>	24,000	—
<b>Total Rights</b> (Cost \$17,304)		<b>—</b>
	<b>Face</b>	<b>Amount</b>
<b>REPURCHASE AGREEMENTS<sup>††,3</sup> - 0.2%</b>		
JPMorgan Chase & Co. issued 12/29/17 at 1.41% due 01/02/18	\$ 382,542	382,542
Bank of America Merrill Lynch issued 12/29/17 at 1.40% due 01/02/18	204,164	204,164
<b>Total Repurchase Agreements</b> (Cost \$586,706)		<b>586,706</b>

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2017

	Shares	Value
<b>SECURITIES LENDING COLLATERAL<sup>†,4</sup> - 4.8%</b>		
<b>Money Market Fund</b>		
First American Government Obligations Fund — Class Z, 1.15% <sup>5</sup>	15,358,681	\$ 15,358,681
<b>Total Securities Lending Collateral</b> (Cost \$15,358,681)		15,358,681
<b>Total Investments - 104.9%</b> (Cost \$205,852,407)		\$ 338,371,461
<b>Other Assets &amp; Liabilities, net - (4.9)%</b>		(15,910,087)
<b>Total Net Assets - 100.0%</b>		\$ 322,461,374

\* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

<sup>1</sup> All or portion of this security is on loan at December 31, 2017.

<sup>2</sup> Security was fair valued by the Valuation Committee at December 31, 2017. The total market value of fair valued securities amounts to \$0, (cost \$17,304) or 0.0% of total net assets.

<sup>3</sup> Repurchase Agreements.

<sup>4</sup> Securities lending collateral.

<sup>5</sup> Rate indicated is the 7 day yield as of December 31, 2017.

ADR — American Depositary Receipt

plc — Public Limited Company